Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
Total Valuation
Arrowhead Pharmaceuticals has a market cap or net worth of $9.62B. The enterprise value is $4.53B.
Market Cap$9.62B
Enterprise Value$4.53B
Share Statistics
Arrowhead Pharmaceuticals has 135,809,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding135,809,560
Owned by Insiders4.10%
Owned by Institutions6.01%
Financial Efficiency
Arrowhead Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.68%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.68%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee1.36M
Profits Per Employee49.45K
Employee Count609
Asset Turnover0.60
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arrowhead Pharmaceuticals is ―. Arrowhead Pharmaceuticals’s PEG ratio is 28.34.
PE Ratio―
PS Ratio5.56
PB Ratio9.90
Price to Fair Value9.90
Price to FCF29.41
Price to Operating Cash Flow438.34
PEG Ratio28.34
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of 829.45M and earned -1.63M in profits. Earnings per share was -0.01.
Revenue829.45M
Gross Profit0.00
Operating Income98.35M
Pretax Income19.79M
Net Income-1.63M
EBITDA98.35M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was 21.84M and capital expenditures -39.47M, giving a free cash flow of -17.62M billion.
Operating Cash Flow21.84M
Free Cash Flow-17.62M
Free Cash Flow per Share-0.13
Dividends & Yields
Arrowhead Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.45
52-Week Price Change213.32%
50-Day Moving Average45.04
200-Day Moving Average24.81
Relative Strength Index (RSI)75.71
Average Volume (3m)2.82M
Important Dates
Arrowhead Pharmaceuticals upcoming earnings date is Feb 10, 2026, After Close (Confirmed).
Last Earnings DateNov 25, 2025
Next Earnings DateFeb 10, 2026
Ex-Dividend Date―
Financial Position
Arrowhead Pharmaceuticals as a current ratio of 4.86, with Debt / Equity ratio of 137.22%
Current Ratio4.86
Quick Ratio4.86
Debt to Market Cap0.02
Net Debt to EBITDA0.23
Interest Coverage Ratio-1.10
Taxes
In the past 12 months, Arrowhead Pharmaceuticals has paid 21.42M in taxes.
Income Tax21.42M
Effective Tax Rate1.08
Enterprise Valuation
Arrowhead Pharmaceuticals EV to EBITDA ratio is 47.14, with an EV/FCF ratio of 29.55.
EV to Sales5.59
EV to EBITDA47.14
EV to Free Cash Flow29.55
EV to Operating Cash Flow25.82
Balance Sheet
Arrowhead Pharmaceuticals has $900.37M in cash and marketable securities with $713.29M in debt, giving a net cash position of $187.09M billion.
Cash & Marketable Securities$900.37M
Total Debt$713.29M
Net Cash$187.09M
Net Cash Per Share$1.38
Tangible Book Value Per Share$5.17
Margins
Gross margin is 96.68%, with operating margin of 11.86%, and net profit margin of -0.20%.
Gross Margin96.68%
Operating Margin11.86%
Pretax Margin2.39%
Net Profit Margin-0.20%
EBITDA Margin11.86%
EBIT Margin0.00%
Analyst Forecast
The average price target for Arrowhead Pharmaceuticals is $67.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$67.50
Price Target Upside-3.70% Downside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast23258.15%
EPS Growth Forecast99.12%